PRNewsWire
16 Jun 2026, 20:44 UTC · 14w ago
Verdict
Headline leans bearish. We score NMRA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Neumora Therapeutics' navacaprant failed both the Phase 3 KOASTAL-2 and KOASTAL-3 trials for major depressive disorder.
More negative than 99% of claims this week
Neumora Therapeutics announced an immediate workforce reduction of approximately 35%.
So whatLarge-scale layoffs immediately following clinical failures indicate severe operational distress and a pivot to survival mode.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 98% of claims this week
Law firm Levi & Korsinsky has initiated an investigation into potential misleading statements by Neumora's officers regarding the navacaprant program.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company reported failed Phase 3 trials for navacaprant and announced a 35% workforce reduction, causing the stock to fall nearly 50%.
More negative than 81% of ticker scores this week
The stock dropped sharply following a detailed short-seller report alleging irregularities.
More negative than 76% of ticker scores this week
The company is the subject of a securities fraud investigation after a stock price drop following an earnings call.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−53.1%
Price agrees with the score
$0.7313 vs $1.56 close before publication (Jun 16) · not market-adjusted
NMRA chart →
